Get notified when SMNR files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Controlled Company (new) — Scilex Holding Company controls over 80% of voting power, giving it control over all stockholder votes including director elections and major corporate decisions.
  • Going Concern (new) — Substantial doubt persists given cash of only $0.1M and operating cash outflow of $2.3M against minimal liquidity; the reported $154.3M net loss is overwhelmingly non-cash (Business Combination charges), not cash burn.
  • Material Weakness (new) — Material weaknesses identified in internal control over financial reporting related to carve-out financial statement preparation and stock-based compensation expense.
  • Single Product / Concentration (new) — Company has only one product candidate (SP-102) in development; no approved products, no revenue, and no alternative pipeline if SP-102 fails to gain approval or achieve commercial success.
  • Cryptocurrency Treasury Strategy (unchanged) — Filing maintains a standing Risks Related to Cryptocurrency disclosure for a named Bitcoin treasury/financing strategy that has not been implemented or tested (1940-Act risk). On minimal cash with going-concern doubt, this non-standard treasury pivot is material even when a related financing line moves out of Recent Developments.
OTC: SMNR Semnur Pharmaceuticals, Inc. 424B3

Semnur Pharmaceuticals secondary offering of up to 12.85M warrants by selling stockholders; company receives no proceeds from resale

Filed December 29, 2025 · ~3 min read

Key Changes

  • high

    Secondary offering by selling stockholders of up to 12,850,000 warrants and underlying shares; Semnur receives zero proceeds from the resale. Company may receive up to $100.7M only if warrant holders exercise for cash (not guaranteed).

    The Offering / Use of Proceeds view on EDGAR →
  • high

    Scilex Holding Company controls over 80% of outstanding common stock, giving it control over all stockholder votes including director elections and major corporate decisions.

    The Offering / Risk Factors view on EDGAR →
  • high

    GAAP net loss of $154.3M for the nine months ended September 30, 2025 (vs. $3.9M prior year), driven overwhelmingly by non-cash SPAC/Business Combination charges; operating cash outflow was only $2.3M. Cash on hand: $0.1M.

    Management's Discussion and Analysis verify on EDGAR →

7 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FUL 10-Q) is open in full — no account needed.

Partner

Trade SMNR commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Jun 27, 2026 · How we verify